Tesamorelin

Q: What should you monitor when using Tesamorelin?

Structure: 44-amino-acid synthetic GHRH analog with a trans-3-hexenoic acid modification for increased potency. The only FDA-approved GHRH analog.

Synthetic GHRH (Growth Hormone Releasing Hormone) analog. FDA-approved for HIV-associated lipodystrophy. Used in bodybuilding for GH release and visceral fat reduction.

Overview

Peptide

Synthetic GHRH (Growth Hormone Releasing Hormone) analog. FDA-approved for HIV-associated lipodystrophy. Used in bodybuilding for GH release and visceral fat reduction.

Effects on Markers

Increases GH and IGF-1 levels, may elevate fasting glucose mildly (less than exogenous GH), can improve lipid profile (reduces triglycerides), reduces visceral adipose tissue, may mildly affect thyroid function (monitor TSH/FT4)

Compound Guide

Structure: 44-amino-acid synthetic GHRH analog with a trans-3-hexenoic acid modification for increased potency. The only FDA-approved GHRH analog.

Dosage:

Standard (FDA-approved): 2mg/day SubQ
Bodybuilding (visceral fat / GH): 1-2mg/day
Anti-aging / general: 1mg/day

Administration:

SubQ injection, abdomen (rotate sites), once daily before bed or morning on empty stomach
27-30g insulin syringe
Must be taken on empty stomach — food blunts GH release

Key Notes:

Stimulates pulsatile GH release (more physiological than exogenous GH injections)
FDA-approved with established safety profile — one of the better-studied peptides
Specifically reduces visceral fat (the dangerous deep abdominal fat)
Improves triglycerides and body composition in clinical trials
Less impact on blood glucose than exogenous GH (preserves physiological feedback)
Monitor: IGF-1, fasting glucose, HbA1c, lipid panel
Can be combined with Ipamorelin for enhanced GH release
Does not cause GH bleed (sustained high levels) like CJC-1295 DAC — more natural pulsatile pattern

Usage History

Markers to Monitor

AST IGF-1 LDL Triglycerides TSH Glucose

Marker Interactions

IGF-1

elevates · significant

Triglycerides

suppresses · moderate

Frequently Asked Questions

SARMs and Peptides Bloodwork: The Complete Monitoring Guide

What blood tests to get before, during, and after SARMs and peptides. Compound-by-compound risk matrix, testing timeline, and action thresholds.

MK-677 & Insulin Resistance: Full HOMA-IR and Glucose Data (2026)

MK-677 raises fasting glucose to 6.8 mmol/L within 4 weeks and HbA1c by 0.2% at 12 months. Complete HOMA-IR data from human studies, when the numbers cross into pre-diabetes, and 5 evidence-based fixes.